Laurus Labs, a pharmaceutical and biotechnology company, has pledged its support to the Rainbow Children's Heart Institute in Hyderabad, with the goal of treating 50 underprivileged children for heart diseases each year.

“We are happy to join hands in saving tiny hearts and further, saving the lives of children. We thank Rainbow Children’s Heart Institute for giving us this opportunity to support a noble cause,” said V V Ravi Kumar, the  Executive Director and CFO of Laurus Labs.

This year's World Heart Day was marked in a unique way by the Rainbow Children's Heart Institute, which hosted an event for over 30 survivors diagnosed with congenital heart disease during their prenatal stages. An additional 20 survivors participated virtually in the event.

Speaking on the occasion, Dr. Shweta Bakhru, Senior Consultant in Pediatric Cardiology, expressed her delight, saying, “We are thrilled to celebrate these little champions. It is worth noting that Congenital Heart Disease is a structural disorder, and identifying it in fetal life plays a crucial role in rectifying this issue.”

She encouraged parents of babies with congenital heart disease not to lose hope but to stay resilient in supporting their child's recovery from this challenge.

Meanwhile, Dr. Chinna Swami Reddy, the Chief Cardiothoracic Surgeon at the institute, also reassured that early detection allows for effective treatment of most congenital heart anomalies.

“Surgical interventions in some cases are lifesaving. We feel immense joy when we can successfully treat these children and send them home with smiles. It’s essential to understand that early intervention is the key. If the defect is diagnosed during the prenatal period, it greatly facilitates successful treatment,” he said.

The Rainbow Children’s Heart Institute, equipped with 110 beds, performs over 700 cardiac procedures and 750 cardiac surgeries every year. It has played a crucial role in saving the lives of hundreds of children facing cardiac issues, both domestically and internationally.